Artificial Insemination Market
The artificial
Insemination market is expected to
reach USD 8.9 billion by 2030 at CAGR of 8.6% during the forecast period
of 2022 to 2030
Artificial Insemination involves depositing sperm into the uterus. In
vitro fertilization (IVF) involves extracting the patient's egg cells to be
fertilized in a lab. The resultant embryo is then transferred to the uterus.
The reimbursement of these techniques is interrelated. Artificial Insemination
costs hundreds of dollars, while IVF costs thousands. Most of the countries in
North America and Europe have a high adoption of treatments related to
fertility. The number of cycles of artificial Insemination covered differs
depending on the country.
The province of New Brunswick, Canada, allows individuals to claim up to
50 percent of eligible costs incurred for IVF or IUI and related drugs, up to a
maximum of USD 5,000. In France, up to four cycles of ART in women up to the
age of 45 are reimbursed, whereas The National Institute for Health and Care
Excellence (UK) recommends support until 3 cycles. Belgium, Denmark, the
Netherlands, and Slovenia are reputed for their most generous reimbursement
policies in Europe, with almost full coverage for up to six cycles. IVF
treatments are fully covered by Belgium, Denmark, and Slovenia states. From
2018, in vitro
fertilization (IVF) and embryo transfer services and
pharmaceuticals are fully financed by Estonian Health Insurance Fund (EHIF). A
Policy Audit on Fertility by ESHRE and supported by Merck & Co. was
published in 2017. It mentioned a wide range of treatment options are available
in the Czech Republic, from Intrauterine Insemination (IUI) to surrogacy. The
donor eggs and sperm and embryos are explicitly protected under Czech law,
which recommends 100% coverage by mandatory health insurance for up to four IVF
cycles and six IUI, for women aged 22-39 years of age. In France, IUI and
IVF/ICSI are fully reimbursed for women under 43 years of age, including up to
six IUIs (one IUI per menstruation cycle).
Major Key
Players:
MRFR recognizes the following companies as the Artificial
Insemination Market Players are — Vitrolife AB, Genea
Limited, Rinovum Women's Health, LLC, Pride Angel, Hi-tech Solutions, Kitazato
Corporation, Fujifilm Irvine Scientific, and Rocket Medical.
Segment Analysis
Global Artificial Insemination Market has been
segmented based on Type and End User.
The market, based on types of artificial Insemination,
has been segregated into intrauterine, intracervical, and Intratubal.
On the basis of end-user, the artificial Insemination
market is classified into hospitals & clinics, fertility centers, and
home-based.
Regional Analysis
Global Artificial Insemination
Market, based on region, has been divided into the Americas, Europe,
Asia-Pacific, and the Middle East and Africa. The Americas accounted for a
larger share of the global artificial Insemination market. The large share is
majorly attributed to the presence of major manufacturers, increasing adoption
of assisted reproductive technologies, technological advancements, and high
disposable income. Boost in the reimbursement scenario in the European region,
rising government initiatives to promote family planning, an increasing number
of patients facing difficulty conceiving, an increasing number of
manufacturers, improving economies, high disposable income per individual, and
increased healthcare spending are driving the growth of the market in this
region. The Asia Pacific region is anticipated to grow at a lucrative CAGR over
the forecast period. For instance, according to a study by Inito (India), a
Bengaluru-based medical technology company, 27.5 million couples suffered from
infertility and were actively seeking children. Also, at least 10-15% of
married couples experienced fertility issues in 2019. Currently, most private
and public health insurers do not include fertility procedures and treatments
under their coverage plans. A research paper in Reproductive Biology and
Endocrinology in 2015 assessed the use of various fertility treatments by
surveying fertility specialists in France, Germany, Italy, Spain, the UK, the
US, China, and Japan. The analysis reported that ART outcomes are varied
by country, with the highest percentage of women facing fertility-related
issues in the US and China. The availability of a large patient pool is
expected to help propel the growth rate of the region.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
